Genentech

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »

Medrio appoints execs from Genentech and NetSuite to board of directors

Thursday, November 15, 2012 08:00 AM

Medrio, a provider of advanced eClinical software as a service (SaaS) for clinical research, has made key appointments to its board of directors: Richard H. Scheller, executive vice president of research at Genentech, and Dave Lipscomb, founder and former executive at NetSuite.

More... »

Orwin joins Array BioPharma’s board of directors

Friday, November 9, 2012 02:29 PM

Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs for the treatment of cancer, has appointed John A. Orwin, CEO of Affymax, to Array's board of directors as part of its continued evolution toward late-stage development and commercialization.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Pascal Soriot named AstraZeneca CEO

Tuesday, August 28, 2012 03:06 PM

AstraZeneca has announced Pascal Soriot’s appointment as the company’s chief executive officer. He will assume the new role and join the AstraZeneca board as an executive director as of Oct. 1.

More... »

Breast cancer drug market will be driven by 3 agents, says Decision Resources

Monday, August 20, 2012 02:18 PM

Three new breast cancer market entrants—Roche/Genentech’s Perjeta (pertuzumab) and trastuzumab-DM1 (T-DM1), and Novartis’s Afinitor (everolimus)—will drive growth in the breast cancer market through 2021, according to Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues.

More... »

FDA approves Lucentis for diabetic macular edema

Monday, August 13, 2012 10:33 AM

The FDA has approved Genentech’s Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

PRA participates in landmark Alzheimer’s prevention trial

Thursday, July 26, 2012 09:52 AM

PRA, a global CRO, is participating in an Alzheimer’s disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background.

More... »

Genentech and Novartis rank as image leaders among oncologists, hematologists

Wednesday, July 25, 2012 09:59 AM

Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study.

More... »